EMAIL THIS PAGE TO A FRIEND

Molecular cancer therapeutics

Inhibition of Homologous Recombination and Promotion of Mutagenic Repair of DNA Double-Strand Breaks Underpins Arabinoside-Nucleoside Analogue Radiosensitization.


PMID 25840584

Abstract

In concurrent chemoradiotherapy, drugs are used to sensitize tumors to ionizing radiation. Although a spectrum of indications for simultaneous treatment with drugs and radiation has been defined, the molecular mechanisms underpinning tumor radiosensitization remain incompletely characterized for several such combinations. Here, we investigate the mechanisms of radiosensitization by the arabinoside nucleoside analogue 9-β-D-arabinofuranosyladenine (araA) placing particular emphasis on the repair of DNA double-strand breaks (DSB), and compare the results to those obtained with fludarabine (F-araA) and cytarabine (araC). Postirradiation treatment with araA strongly sensitizes cells to ionizing radiation, but leaves unchanged DSB repair by NHEJ in logarithmically growing cells, in sorted G1 or G2 phase populations, as well as in cells in the plateau phase of growth. Notably, araA strongly inhibits DSB repair by homologous recombination (HRR), as assessed by scoring ionizing radiation-induced RAD51 foci, and in functional assays using integrated reporter constructs. Cells compromised in HRR by RNAi-mediated transient knockdown of RAD51 show markedly reduced radiosensitization after treatment with araA. Remarkably, mutagenic DSB repair compensates for HRR inhibition in araA-treated cells. Compared with araA, F-araA and araC are only modestly radiosensitizing under the conditions examined. We propose that the radiosensitizing potential of nucleoside analogues is linked to their ability to inhibit HRR and concomitantly promote the error-prone processing of DSBs. Our observations pave the way to treatment strategies harnessing the selective inhibitory potential of nucleoside analogues and the development of novel compounds specifically utilizing HRR inhibition as a means of tumor cell radiosensitization.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB1406364
Anti-RAD51 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
SAB2101936
Anti-RAD51 antibody produced in rabbit, affinity isolated antibody
SAB2700175
Anti-RAD51 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
HPA039310
Anti-RAD51 antibody produced in rabbit, Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
SAB4502565
Anti-RAD51, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB4502566
Anti-RAD51, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB1406602
Anti-XRCC2 antibody produced in mouse, purified immunoglobulin, buffered aqueous solution
X3878 Anti-XRCC2 antibody produced in rabbit, affinity isolated antibody, ammonium sulfate suspension
SAB2102727
Anti-XRCC2 antibody produced in rabbit, affinity isolated antibody
SAB1411401
Anti-XRCC2 antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
WH0005888M1
Monoclonal Anti-RAD51 antibody produced in mouse, clone 2E5-E5, purified immunoglobulin, buffered aqueous solution
SAB1404293
Monoclonal Anti-RAD51 antibody produced in mouse, clone 4C11-B4, purified immunoglobulin, buffered aqueous solution
SAB1402394
Monoclonal Anti-XRCC2 antibody produced in mouse, clone 2H4, purified immunoglobulin, buffered aqueous solution